FEDRATINIB HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for fedratinib hydrochloride and what is the scope of patent protection?
Fedratinib hydrochloride
is the generic ingredient in one branded drug marketed by Bristol-myers and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Fedratinib hydrochloride has one hundred and ten patent family members in forty countries.
One supplier is listed for this compound.
Summary for FEDRATINIB HYDROCHLORIDE
International Patents: | 110 |
US Patents: | 5 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 30 |
Clinical Trials: | 23 |
Patent Applications: | 18 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FEDRATINIB HYDROCHLORIDE |
What excipients (inactive ingredients) are in FEDRATINIB HYDROCHLORIDE? | FEDRATINIB HYDROCHLORIDE excipients list |
DailyMed Link: | FEDRATINIB HYDROCHLORIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FEDRATINIB HYDROCHLORIDE
Generic Entry Date for FEDRATINIB HYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for FEDRATINIB HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Joseph Jurcic | Phase 1 |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
Celgene International II S.á.r.l. | Phase 2 |
Paragraph IV (Patent) Challenges for FEDRATINIB HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
INREBIC | Capsules | fedratinib hydrochloride | 100 mg | 212327 | 1 | 2023-08-16 |
US Patents and Regulatory Information for FEDRATINIB HYDROCHLORIDE
International Patents for FEDRATINIB HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Slovenia | 2635282 | ⤷ Sign Up | |
China | 108125923 | 用于治疗骨髓纤维化的组合物和方法 (Compositions and methods for treating myelofibrosis) | ⤷ Sign Up |
South Korea | 20210102192 | 골수증식성 장애를 치료하는 방법 | ⤷ Sign Up |
Russian Federation | 2013126121 | КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ МИЕЛОФИБРОЗА | ⤷ Sign Up |
Ukraine | 109412 | 5-МЕТИЛ-N2-[4-(4-МЕТИЛПІПЕРАЗИН-1-ІЛ)ФЕНІЛ]-ПІРИМІДИН-2,4-ДІАМІН ТА ЙОГО ЗАСТОСУВАННЯ В СПОСОБІ ОДЕРЖАННЯ СПОЛУКИ | ⤷ Sign Up |
Canada | 2816957 | COMPOSITIONS ET PROCEDES DE TRAITEMENT DE LA MYELOFIBROSE (COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS) | ⤷ Sign Up |
New Zealand | 567851 | Bi-aryl meta-pyrimidine inhibitors of kinases | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FEDRATINIB HYDROCHLORIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1951684 | C202130029 | Spain | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, O UN HIDRATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR MONOHIDRATO DE DIHIDROCLORURO DE FEDRATINIB; NATIONAL AUTHORISATION NUMBER: EU/1/20/1514; DATE OF AUTHORISATION: 20210208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1514; DATE OF FIRST AUTHORISATION IN EEA: 20210208 |
1951684 | 14/2021 | Austria | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER EIN PHARMAZEUTISCH ANNEHMBARES HYDRAT DAVON, INSBESONDERE FEDRATINIB-DIHYDROCHLORID-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/20/1514 (MITTEILUNG) 20210209 |
1951684 | 132021000000053 | Italy | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, O UN SUO IDRATO FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE FEDRATINIB DICLORIDRATO MONOIDRATO(INREBIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1514, 20210209 |
1951684 | C 2021 012 | Romania | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB, SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA, SAU UN HIDRAT ACCEPTABIL FARMACEUTIC AL ACESTUIA, IN PARTICULAR DICLORHIDRAT DE FEDRATINIB MONOHIDRAT; NATIONAL AUTHORISATION NUMBER: EU/1/20/1514; DATE OF NATIONAL AUTHORISATION: 20210208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1514; DATE OF FIRST AUTHORISATION IN EEA: 20210208 |
1951684 | CA 2021 00011 | Denmark | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET FARMACEUTISK ACCEPTABELT HYDRAT DERAF, ISAER FEDRATINIB-DIHYDROCHLORIDMONOHYDRAT; REG. NO/DATE: EU/1/20/1514 20210209 |
1951684 | C01951684/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67792 01.07.2021 |
1951684 | 122021000023 | Germany | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON ODER EIN PHARMAZEUTISCH UNBEDENKLICHES HYDRAT DAVON, INSBESONDERE FEDRATINIB-DIHYDROCHLORID-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/20/1514 20210208 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |